Geode Capital Management LLC Purchases 62,875 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Geode Capital Management LLC lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 4.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 1,472,899 shares of the specialty pharmaceutical company’s stock after buying an additional 62,875 shares during the period. Geode Capital Management LLC’s holdings in Supernus Pharmaceuticals were worth $73,215,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp lifted its holdings in shares of Supernus Pharmaceuticals by 2.9% during the 2nd quarter. State Street Corp now owns 2,208,560 shares of the specialty pharmaceutical company’s stock worth $69,614,000 after acquiring an additional 63,210 shares during the period. Stephens Investment Management Group LLC lifted its holdings in shares of Supernus Pharmaceuticals by 4.5% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company’s stock worth $69,904,000 after acquiring an additional 61,120 shares during the period. Woodline Partners LP lifted its holdings in shares of Supernus Pharmaceuticals by 63.5% during the 3rd quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after acquiring an additional 490,835 shares during the period. Bank of America Corp DE lifted its holdings in shares of Supernus Pharmaceuticals by 67.1% during the 3rd quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock worth $40,282,000 after acquiring an additional 338,584 shares during the period. Finally, Sofinnova Investments Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 53.5% during the 2nd quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company’s stock worth $25,192,000 after acquiring an additional 278,575 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SUPN. Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 25th. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Finally, Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 23rd. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $62.17.

Insider Buying and Selling

In related news, VP Padmanabh P. Bhatt sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $50.28, for a total transaction of $2,514,000.00. Following the completion of the transaction, the vice president directly owned 17,044 shares in the company, valued at $856,972.32. This represents a 74.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Frederick M. Hudson sold 5,369 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $50.61, for a total transaction of $271,725.09. Following the transaction, the director owned 60,413 shares of the company’s stock, valued at approximately $3,057,501.93. This represents a 8.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 97,619 shares of company stock worth $4,908,275 in the last three months. 8.80% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Price Performance

SUPN stock opened at $44.48 on Tuesday. The company has a 50 day simple moving average of $49.11 and a 200 day simple moving average of $49.56. The stock has a market cap of $2.58 billion, a price-to-earnings ratio of -87.22, a P/E/G ratio of 0.96 and a beta of 0.55. Supernus Pharmaceuticals, Inc. has a 1 year low of $30.83 and a 1 year high of $59.68.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.